Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2026 08:30 ET | Source: Profusa, Inc.

Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value

Company focusing resources on near-term commercial milestones; European CE Mark process and Healthcare Research revenue opportunities Process intended to evaluate strategic growth alternatives to...
May 05, 2026 08:09 ET | Source: SNS Insider pvt ltd

Colonoscopy Devices Market Size Projected to Hit USD 5.55 Billion by 2035, Driven by Rising Colorectal Cancer Screening– SNS Insider

Austin, United States, May 05, 2026 (GLOBE NEWSWIRE) -- “According to SNS Insider, the global Colonoscopy Devices Market size was estimated at USD 3.33 billion in 2025 and is projected to reach USD...
May 05, 2026 08:00 ET | Source: Filana Therapeutics, Inc.

Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII

AUSTIN, Texas, May 05, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for...
May 05, 2026 08:00 ET | Source: Septerna, Inc.

Septerna to Present at Bank of America Securities Health Care Conference

SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug...
May 05, 2026 08:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline

Company advances its leadership in MASH with clinical-stage, genetically targeted siRNA asset from Arrowhead PharmaceuticalsPrecision approach targets patients who have a mutation in the PNPLA3 gene,...
May 05, 2026 07:50 ET | Source: Neuronetics

Neuronetics Reports First Quarter 2026 Financial and Operating Results

MALVERN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a vertically integrated, commercial stage, medical technology and healthcare company...
May 05, 2026 07:00 ET | Source: Seres Therapeutics, Inc.

Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Clinical readout from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected in the coming weeks Seres maintains operational focus on advancing live...
May 05, 2026 07:00 ET | Source: Climb Bio, Inc.

Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts

Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development Budoprutug pMN, ITP, and SLE clinical trials enrolling to plan; Fast...
May 05, 2026 07:00 ET | Source: Fractyl Health, Inc.

Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference

BURLINGTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat...
May 05, 2026 07:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

-- IMCIVREE® (setmelanotide) launched in the U.S. for acquired hypothalamic obesity; more than 150 patient start forms received in the first six weeks following FDA approval on March 19, 2026 -- --...